Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.73 |
| ▸ | AKT2 | P31751 | 2/20 | 0.72 |
| ▸ | GSK3B | P49841 | 2/20 | 0.72 |
| ▸ | JAK3 | P52333 | 8/20 | 0.71 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.65 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.65 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.65 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.65 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.65 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.65 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.65 |
| ▸ | BTK | Q06187 | 3/20 | 0.60 |
| ▸ | KIT | P10721 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 4/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740561 | 0.89 | DOT1L (0.71) | DOT1LAKT2GSK3BJAK3PRKAB2 | |
| SCHEMBL1531444 | 0.84 | DOT1L (1.00) | DOT1LAKT2GSK3BJAK3PRKAB2 | |
| SCHEMBL1531600 | 0.84 | DOT1L (1.00) | DOT1LAKT2GSK3BJAK3PRKAB2 | |
| SCHEMBL1531446 | 0.84 | DOT1L (1.00) | DOT1LAKT2GSK3BJAK3PRKAB2 | |
| SCHEMBL4125661 | 0.84 | AKT2 (1.00) | DOT1LAKT2GSK3BJAK3KIT | |
| SCHEMBL20862485 | 0.83 | JAK3 (1.00) | DOT1LAKT2GSK3BJAK3PRKAB2 | |
| SCHEMBL2020261 | 0.83 | DOT1L (0.74) | DOT1LAKT2GSK3BJAK3PRKAB2 | |
| SCHEMBL3954391 | 0.83 | JAK3 (1.00) | DOT1LAKT2GSK3BJAK3PRKAB2 | |
| SCHEMBL2019326 | 0.83 | DOT1L (0.74) | DOT1LAKT2GSK3BJAK3PRKAB2 | |
| SCHEMBL2019327 | 0.83 | DOT1L (0.74) | DOT1LAKT2GSK3BJAK3PRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| CN-101484173-A | Pharmaceutical combinations of pk inhibitors and other active agents | ASTEX THERAPEUTICS LTD (GB) | 2009-07-15 | — | — | CN | disclosed |
| CN-101479263-A | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD (GB) | 2009-07-08 | — | — | CN | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090082370-A1 | Pharmaceutical Combinations of PK Inhibitors and Other Active Agents | ASTEX THERAPEUTICS LIMITED (GB) | 2009-03-26 | — | — | US | disclosed |
| WO-2007125315-A2 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253718-A1 | Pharmaceutical Compounds | GRK3, CNKSR1, CSNK1G3 | DOT1L 2116/4885AKT2 153/4885GSK3B 157/4885 |
| US-20090082370-A1 | Pharmaceutical Combinations of PK Inhibitors and Other Active Agents | PKN2, PKN1, PKN3 | DOT1L 1817/4885AKT2 523/4885GSK3B 109/4885 |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | OXSR1, CDK1, CDK3 | DOT1L 2031/4885AKT2 999/4885GSK3B 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.